Literature DB >> 19166698

Relation of serum sodium level to long-term outcome after a first hospitalization for heart failure with preserved ejection fraction.

Dan Rusinaru1, Otilia Buiciuc, Laurent Leborgne, Michel Slama, Ziad Massy, Christophe Tribouilloy.   

Abstract

Hyponatremia is a predictor of adverse short-term outcomes in patients with acute heart failure (HF). The impact of hyponatremia on long-term survival in patients with HF with preserved ejection fraction (HFPEF) has not been evaluated. Our aim was to prospectively assess the impact of baseline natremia and changes in sodium level during hospitalization on 7-year outcome in 358 patients surviving a first hospitalization for HFPEF. On admission, hyponatremia (sodium <136 mEq/L) was diagnosed in 91 patients (25.4%). Baseline hyponatremia was associated with an increased risk of overall (hazard ratio [HR] 1.98, 95% confidence interval [CI] 1.50 to 2.61) and cardiovascular mortality (HR 1.92, 95% CI 1.36 to 2.73). After adjustment for covariates, the relations remained significant. Seven-year relative survival (observed/expected survival) of hyponatremic patients was lower than that of patients with normal baseline natremia (31% vs 63%). The association of sodium and risk of death appeared linear across quartiles of baseline natremia and slightly stronger at the lowest of sodium values. At discharge, 45 patients with low baseline sodium had normal natremia (49%) and 46 had persistent hyponatremia (51%). Patients with normalized natremia at discharge had excess 7-year overall mortality compared with the normonatremic group (HR 1.50, 95% CI 1.03 to 2.19). Patients with persistent hyponatremia had the lowest 7-year survival (HR 2.67, 95% CI 1.89 to 3.78). After adjustment for covariates, patients with persistent hyponatremia had an impressive increase in relative risk of overall mortality compared with patients with normal baseline natremia. In conclusion, hyponatremia is a powerful predictor of long-term mortality in patients with HFPEF. Patients with HFPEF and persistent hyponatremia are at high risk of adverse outcomes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19166698     DOI: 10.1016/j.amjcard.2008.09.091

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  13 in total

Review 1.  Improvement of hyponatremia is associated with lower mortality risk in patients with acute decompensated heart failure: a meta-analysis of cohort studies.

Authors:  Jinhui Wang; Weijian Zhou; Xiaoning Yin
Journal:  Heart Fail Rev       Date:  2019-03       Impact factor: 4.214

2.  Serial sodium values and adverse outcomes in heart failure with preserved ejection fraction.

Authors:  Tasnim F Imran; Katherine E Kurgansky; Yash R Patel; Ariela R Orkaby; Robert R McLean; Yuk-Lam Ho; Kelly Cho; J Michael Gaziano; Luc Djousse; David R Gagnon; Jacob Joseph
Journal:  Int J Cardiol       Date:  2019-03-22       Impact factor: 4.164

Review 3.  Hyponatremia in acute decompensated heart failure: mechanisms, prognosis, and treatment options.

Authors:  Geoffrey T Jao; Jun R Chiong
Journal:  Clin Cardiol       Date:  2010-11       Impact factor: 2.882

4.  Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma.

Authors:  A N Jeppesen; H K Jensen; F Donskov; N Marcussen; H von der Maase
Journal:  Br J Cancer       Date:  2010-02-09       Impact factor: 7.640

5.  Hyponatremia as a powerful prognostic predictor for Japanese patients with clear cell renal cell carcinoma treated with a tyrosine kinase inhibitor.

Authors:  Junya Furukawa; Hideaki Miyake; Yuji Kusuda; Masato Fujisawa
Journal:  Int J Clin Oncol       Date:  2014-06-04       Impact factor: 3.402

6.  Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients.

Authors:  Savina Nodari; Geoffrey T Jao; Jun R Chiong
Journal:  Int J Nephrol Renovasc Dis       Date:  2010-05-10

7.  Hyponatremia improvement is associated with a reduced risk of mortality: evidence from a meta-analysis.

Authors:  Giovanni Corona; Corinna Giuliani; Joseph G Verbalis; Gianni Forti; Mario Maggi; Alessandro Peri
Journal:  PLoS One       Date:  2015-04-23       Impact factor: 3.240

8.  Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure.

Authors:  Kentaro Jujo; Katsumi Saito; Issei Ishida; Yuho Furuki; Ahsung Kim; Yuki Suzuki; Haruki Sekiguchi; Junichi Yamaguchi; Hiroshi Ogawa; Nobuhisa Hagiwara
Journal:  ESC Heart Fail       Date:  2016-03-31

9.  Moderate hyponatremia is associated with increased risk of mortality: evidence from a meta-analysis.

Authors:  Giovanni Corona; Corinna Giuliani; Gabriele Parenti; Dario Norello; Joseph G Verbalis; Gianni Forti; Mario Maggi; Alessandro Peri
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

10.  Tolvaptan vs. furosemide-based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA-AHF).

Authors:  Tien M H Ng; Luanda P Grazette; Michael W Fong; Andrew J Yoon; Mimi Lou; Allen Kuo; Rani Y Upadhyay; Emily E Han; Anilkumar Mehra; Uri Elkayam
Journal:  ESC Heart Fail       Date:  2020-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.